6.16
-0.08
(-1.28%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.00 - 6.24 |
| 52 week | 3.07 - 6.57 |
| Open | 6.00 |
| Vol / Avg. | 28,250.00/26,066.00 |
| Mkt cap | 55.27M |
| P/E | 238.48 |
| Div/yield | - |
| EPS | 0.03 |
| Shares | 8.97M |
| Beta | 1.82 |
| Inst. own | 63% |
Events
Jul 29, 2013
Q2 2013 IRIDEX Earnings Release
May 2, 2013
Q1 2013 IRIDEX Earnings Conference Call -
Apr 29, 2013
Q1 2013 IRIDEX Earnings Release
Feb 28, 2013
Q4 2012 IRIDEX Earnings Conference Call -
Feb 27, 2013
Q4 2012 IRIDEX Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -7.04% | 6.46% |
| Operating margin | -7.35% | 8.25% |
| EBITD margin | - | 3.18% |
| Return on average assets | -7.21% | 6.98% |
| Return on average equity | -9.18% | 10.23% |
| Employees | 106 | - |
| Carbon Disclosure Rating | - | - |
Address
1212 Terra Bella Avenue
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
IRIDEX Corporation is a worldwide provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat eye diseases in ophthalmology. The Company focuses primarily on its ophthalmology. The Company�s ophthalmology products are sold in the United States predominantly through a direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company�s ophthalmology offering include IQ and OcuLight laser systems, consumables and service and support activities. The Company �s family of IQ products includes IQ 532, IQ 577 and IQ 810 laser photocoagulation systems and its OcuLight products include OcuLight TX, OcuLight Symphony (Laser Delivery System), OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. In February 2012, The Company sold its aesthetics business to Cutera, Inc.
Officers and directors
| Will M. Moore Jr. | Chairman of the Board, Interim President and Chief Executive Officer | |
| James H Mackaness | Chief Financial Officer, Chief Operating Officer | |
| Eduardo Arias | Senior Vice President - Global Sales | |
| Scott A. Shuda | Director | |
| Sanford Fitch | Independent Director | |
| Garrett A. Garrettson Ph.D. | Independent Director | |
| James B Hawkins | Independent Director | |
| Ruediger Naumann-Etienne Ph.D. | Independent Director |